{"Clinical Trial ID": "NCT02005887", "Intervention": ["INTERVENTION 1:", "Bras A: Triptorelin + Letrozol", "A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles", "Triptorelin: Triptorelin 3.75 mg injected into muscle on day 1 every 28 days for 6 cycles (1 cycle = 28 days)", "Letrozole: Letrozole 2.5 mg orally daily for 6 cycles", "INTERVENTION 2:", "Bras B: Degarelix + Letrozol", "Bras B: Degarelix 240 mg s.c. on day 1 of Cycle 1, followed by 80 mg s.c. on day 1 of Cycles 2 to 6 + Letrozole 2.5 mg per day orally for 6 cycles", "Degar\u00e9lix: Degar\u00e9lix 240 mg injected under the skin as two 120 mg injections on the first day of treatment followed by an 80 mg injection on the first day of cycles 2 to 6 (1 cycle = 28 days)", "Letrozole: Letrozole 2.5 mg orally daily for 6 cycles"], "Eligibility": ["Incorporation criteria:", "Female", "The premenopausal state measured within 14 days prior to randomization: Estradiol (E2) must be greater than 54 pg/mL (or greater than 198 pmol/L)", "- 18 years", "Performance Status - Eastern Cooperative Oncology Group (ECOG) 0-1", "Invasive breast cancer confirmed histologically: primary tumour greater than 2 cm Diameter, any nodal stage, no evidence of metastases (M0)", "A primary tumour should have an ER and a PgR > 50% of the cells", "The primary tumour should be HER2-negative (by IHC and/or ISH)", "Haematopoietic status: absolute neutrophil count 1.5 \u00d7 109/L, platelet count 100 \u00d7 109/L, hemoglobin 9 g/dL", "Hepatic status: Total serum bilirubin 1.5 \u00d7 upper limit of normal (ULN), AST and ALT 2.5 \u00d7 ULN, alkaline phosphatase 2.5 \u00d7 ULN", "Renal status: Creatinine 1.5 \u00d7 ULN", "- Negative serum pregnancy test within 2 weeks (preferably 7 days) prior to randomization.", "The patient should be prepared to use effective non-hormonal contraception after the pregnancy test and until surgery. Oral hormonal contraceptives, injections or implants or medicated IUDs are not allowed within 2 months prior to randomization and during the trial.", "Prior fertility treatment is allowed but must have been discontinued at least 12 months prior to randomisation.", "The patient completed the initial questionnaire on the symptoms reported by the patient.", "The written consent must be signed and dated by the patient and investigator prior to randomization.", "The patient has been informed and accepts data transfer and processing in accordance with national data protection guidelines.", "The patient agrees that blood samples should be taken to determine the primary criterion.", "The patient agrees to make the tumour available for submission to the central pathology examination and for translation studies under this protocol", "- Exclusion criteria:", "Postmenopausal menopausal", "Any hormonal treatment (e.g. oral, injection, implant or drug-treated IDU) in the previous 2 months", "Presence of an overexpression or an amplification HER2", "Has received any prior treatment for invasive primary breast cancer", "Receipt of any similar GnRH or SERM or AI within 12 months prior to randomization", "A history of malignant neoplasms over the past 10 years, with the exception of skin carcinoma, skin carcinoma, in situ cervix carcinoma, in situ bladder carcinoma", "Previous ipsilateral breast cancer (invasive or in situ) at any time", "Inflammatory breast cancer", "\u2022 Bilateral invasive breast cancer", "\u2022 Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (180/110), unstable diabetes mellitus, resting dyspnoea or chronic oxygen treatment", "A concomitant illness or condition that would make the subject inappropriate for participation in the study or any serious medical condition that would interfere with the safety of the subject", "Resolved or unstable, serious adverse events resulting from the prior administration of another experimental medicinal product", "- Active or uncontrolled infection CTCAE v.4 grade 2 or more", "Dementia, altered mental condition or any psychiatric condition that prevents understanding or informed consent", "The treatment with a research officer must have stopped at least 30 days prior to randomization.", "\u2022 Pregnant or lactating women; breast-feeding should stop before randomisation."], "Results": ["Performance measures:", "Time to optimize ovarian function suppression", "Time between the first injection of degarelix or triptorelin and the first assessment of the level of 17-\u03b2-estradiol (E2) evaluated centrally in the optimal suppression range of ovarian function ( 2.72 pg/mL or 10 pmol/L) during the 6 cycles of neoadjuvant treatments.", "Duration: up to 24 weeks", "Results 1:", "Title of the arm/group: Arm A: Triptorelin + Letrozol", "Description of the arm/group: arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles", "Triptorelin: Triptorelin 3.75 mg injected into muscle on day 1 every 28 days for 6 cycles (1 cycle = 28 days)", "Letrozole: Letrozole 2.5 mg orally daily for 6 cycles", "Total number of participants analysed: 26", "Median (95% confidence interval)", "Unit of measurement: days 14 (8-14)", "Results 2:", "Title of arm/group: Arm B: Degarelix + Letrozol", "Description of the arm/group: arms B: Degarelix 240 mg n.e.c. on day 1 of Cycle 1, followed by 80 mg n.e.c. on day 1 of Cycles 2 to 6 + Letrozole 2.5 mg per day orally for 6 cycles", "Degar\u00e9lix: Degar\u00e9lix 240 mg injected under the skin as two 120 mg injections on the first day of treatment followed by an 80 mg injection on the first day of cycles 2 to 6 (1 cycle = 28 days)", "Letrozole: Letrozole 2.5 mg orally daily for 6 cycles", "Total number of participants analysed: 25", "Median (95% confidence interval)", "Unit of measurement: days 3 (3 to 3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/26 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}